Evidence map›Paper›PMID 34345605›Full record

ArticleJournal of advanced pharmaceutical technology & research

Putu Gita Maya, Widyaswari Mahayasih, Harizal, Herman, Islamudin Ahmad

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Erratum:Journal of advanced pharmaceutical technology & research
    Article
  4. Dipeptidyl peptidase IV inhibition of phytocompounds fromJournal of advanced pharmaceutical technology & research
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Putu Gita MayaDepartment of Pharmacy, Faculty of Health Sciences, Universitas Esa Unggul, West Jakarta, DKI Jakarta, Indonesia.
Widyaswari MahayasihDepartment of Pharmacy, Faculty of Health Sciences, Universitas Esa Unggul, West Jakarta, DKI Jakarta, Indonesia.
HarizalDepartment of Pharmacy, Faculty of Health Sciences, Universitas Esa Unggul, West Jakarta, DKI Jakarta, Indonesia.
HermanLaboratory of Pharmaceutical Research and Development of FARMAKA TROPIS, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, Indonesia.
Islamudin AhmadDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Mulawarman, Samarinda, East Kalimantan, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (S-CoV-2 Mpro) is one of the main targets in designing antiviral against SARS-CoV-2.

Indexed as

Asiaticosidecoronavirus disease-2019isothankunic acidmolecular dockingpolyacetylenestriterpenoids

Identifiers

PMID34345605
PMCPMC8300333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.